key: cord-0703348-rj4diq0x
authors: Go, Alan S.; Reynolds, Kristi; Tabada, Grace H.; Prasad, Priya A.; Sung, Sue Hee; Garcia, Elisha; Portugal, Cecilia; Fan, Dongjie; Pai, Ashok P.; Fang, Margaret C.
title: Covid-19 and Risk of Venous Thromboembolism in Ethnically Diverse Populations
date: 2021-07-19
journal: Chest
DOI: 10.1016/j.chest.2021.07.025
sha: a5ca2e2c50caea7237f91d72803f03040939c763
doc_id: 703348
cord_uid: rj4diq0x

Background Limited existing data suggest the novel coronavirus disease 2019 (Covid-19) may increase risk for venous thromboembolism (VTE) but information from large, ethnically diverse populations with appropriate controls are lacking. Research Question Does the rate of VTE among adults hospitalized with Covid-19 differ from matched hospitalized controls without Covid-19? Study Design and Methods We conducted a retrospective study among hospitalized adults with laboratory-confirmed Covid-19 and hospitalized adults without evidence of Covid-19 matched on age, gender, race/ethnicity, acute illness severity, and month of hospitalization between February-August 2020 from two integrated healthcare delivery systems with 36 hospitals. Outcomes included VTE (deep venous thrombosis or pulmonary embolism ascertained using diagnosis codes combined with validated natural language processing algorithms applied to electronic health records) and death from any cause at 30 days. Fine and Gray hazards regression was performed to evaluate the association of Covid-19 with VTE after accounting for competing risk of death and residual differences between groups, as well as identifying predictors of VTE in patients with Covid-19. Results We identified 6,319 adults with Covid-19 and 6,319 matched adults without Covid-19, with mean (SD) age of 60.0 (17.2) years, 46% women, 53.1% Hispanic, 14.6% Asian/Pacific Islander and 10.3% Black. During 30-day follow-up, 313 validated VTE (160 Covid-19, 153 controls) and 1172 deaths (817 Covid-19, 355 controls) occurred. Adults with Covid-19 had a more than threefold adjusted risk of VTE (adjusted hazard ratio 3.48, 95% Confidence Interval 2.03-5.98) compared with matched controls. Predictors of VTE in Covid-19 patients included age ≥55 years, Black race, prior VTE, diagnosed sepsis, prior moderate or severe liver disease, body mass index ≥40 kg/m2, and platelet count >217 k/mcL. Interpretation Among ethnically diverse hospitalized adults, Covid-19 infection increased the risk of VTE, and selected patient characteristics were associated with higher thromboembolic risk in the setting of Covid-19.

Interpretation: Among ethnically diverse hospitalized adults, Covid-19 infection increased the risk of VTE, and selected patient characteristics were associated with higher thromboembolic risk in the setting of Covid-19.

Coronavirus disease 2019 (Covid-19) remains a leading cause of death internationally. 1, 2 In addition to respiratory and multi-organ failure, thrombosis is an increasing concern, particularly among adults hospitalized with Covid-19. Recent studies have reported that Covid-19 is associated with abnormal coagulation profiles, [3] [4] [5] and a recent meta-analysis suggested it may predispose to venous thromboembolic events (VTE) and other types of thromboembolism, as well as worse post-VTE outcomes. 6 However, few data exist about the incidence of VTE associated with Covid-19 in large, ethnically diverse populations. Existing studies have primarily focused only on critically ill Covid-19 patients, with uncertainty about VTE risk compared to appropriate control patients without Covid-19 and after accounting for the competing risk of non-VTE-related death associated with Covid-19. 6 These insights are key to understand who may potentially benefit from prevention strategies given that limited evidence exists to help guide which Covid-19 patients should be offered initial or post-hospitalization VTE prophylaxis and at what anticoagulation intensity. 7 To address these knowledge gaps, we evaluated the rate of VTE among a large, ethnically diverse cohort of adults hospitalized with Covid-19 compared with matched controls without Covid-19, and also identified predictors of VTE in patients with Covid-19.

The source population was derived from Kaiser Permanente Northern California and Southern California integrated healthcare delivery systems, which provide comprehensive care that is captured through electronic medical record (EMR) systems covering inpatient, emergency department and outpatient settings. Kaiser Permanente Northern California serves >4.5 million members at 21 hospital-based medical centers and Kaiser Permanente Southern California serves >4.6 million members at 15 hospital-based medical centers in California, USA.

Their membership is highly representative of their local surrounding and statewide population with regards to age, gender and race and ethnicity. 8, 9 Institutional review boards at Kaiser Permanente Northern California and Southern California approved the study (IRB No. 1279252) . A waiver of informed consent was obtained due to the nature of this retrospective, data-only study.

The Kaiser Permanente Virtual Data Warehouse (VDW) and EMR were the primary data sources for patient identification and characterization at participating sites. The VDW is comprised of EMR-based datasets with linked sociodemographic, administrative, pharmacy, laboratory results, and health care utilization data. 10, 11 We performed a retrospective cohort study of hospitalized adults with Covid-19 and matched hospitalized control patients without evidence of Covid-19 (Figure 1) . We first identified adults (age ≥18 years) hospitalized at a Kaiser Permanente facility between February 1 through August 31, 2020. We excluded persons with missing gender or <12 months of continuous enrollment and pharmacy benefits before admission to ensure adequate data on covariates.

We identified patients with laboratory-confirmed Covid-19 based on polymerase chain reaction testing for SARS-CoV-2 ascertained through Kaiser Permanente laboratory systems, which also includes results for approved assays from outside laboratories. We assigned each patient's index date as the admission date following the first positive SARS-CoV-2 test within 30 days before or during the index hospitalization.

We next identified a matched cohort of hospitalized adults without evidence of Covid-19 (i.e., negative SARS-CoV-2 polymerase chain reaction test result or not having received a test up to 30 days before or during the index hospitalization). If the patient had a negative test result, the hospitalization within 30 days of that result was used as the index hospitalization; if the J o u r n a l P r e -p r o o f patient was hospitalized but never received SARS-CoV-2 testing, their index date was assigned as the first admission date during the study period. We next performed 1:1 matching between Covid-19 and control patients based on Laboratory-Based Acute Physiology Score, Version 2 (LAPS2) at admission, age (±1 year), self-reported gender, self-reported race and Hispanic ethnicity, and calendar month of index hospitalization. The LAPS2 score is a validated, integrated physiology-based severity of illness score calculated from multiple laboratory results and vital signs that is highly predictive of short-term mortality. 12 Outcomes Censoring occurred at the earliest of a VTE event, death, health plan disenrollment or completing 30 days of follow-up.

The primary outcome was acute VTE (deep venous thrombosis or pulmonary embolism) on or after index date, which could occur in the inpatient or post-discharge outpatient or emergency department setting. We initially searched EMR systems for inpatient encounters with primary or secondary International Classification of Disease, Tenth Edition (ICD-10) diagnosis codes for deep venous thrombosis and pulmonary embolism (codes available on request). Postdischarge emergency department or outpatient encounters also required evidence of a relevant radiology procedure (e.g., chest computerized tomography angiogram or extremity ultrasound) within 14 days of an encounter with an associated VTE diagnosis code. Given we previously demonstrated the suboptimal accuracy of VTE diagnosis codes in inpatient, emergency department and outpatient settings within participating sites, 13 we developed and validated a rules-based natural language processing algorithm to identify valid acute VTE events from unstructured EMR data within Kaiser Permanente Northern and Southern California. The algorithm was developed and trained on 479 confirmed VTE events, with a positive predictive value of 95% and negative predictive value of 97% compared to physician adjudication of medical records using standardized diagnostic criteria. 14 J o u r n a l P r e -p r o o f

We identified deaths using comprehensive data from health plan databases (including inpatient and emergency department deaths, and proxy reports), state death certificate files, and Social Security Administration Death Master File. 10, [15] [16] [17] Information on presumed cause(s) of death was unavailable.

Covariates Demographic characteristics (age, self-reported gender, self-reported race and Hispanic ethnicity) were collected from EMR data.

We ascertained relevant medical history up to 5 years before index date using previously validated approaches based on ICD-9 and ICD-10 diagnosis and procedure codes, Current Procedure Terminology (CPT) procedure codes, laboratory results, pharmacy dispensings and vital sign data. 10, 11, [18] [19] [20] This included cardiovascular conditions (acute myocardial infarction, unstable angina, percutaneous coronary intervention, coronary artery bypass surgery, heart failure, rheumatic heart disease, atrial fibrillation/flutter, mitral or aortic valvular disease, peripheral artery disease, ischemic stroke or transient ischemic attack), cardiovascular risk factors (diabetes mellitus, hypertension, dyslipidemia, smoking status), and other medical history (coagulopathy, hypercoagulable hematologic conditions, thrombophilia, chronic lung disease, liver disease, peptic ulcer disease, intracranial hemorrhage, hospitalization for gastrointestinal hemorrhage, hospitalization for other bleeding, hemiplegia or paraplegia, inflammatory bowel disease, cancer, prior mechanical fall, dementia, depression, and substance or alcohol abuse). We also included information on diagnosed sepsis during the index hospitalization based on diagnostic codes. We ascertained kidney function from estimated glomerular filtration rate before index date using the CKD-EPI equation 21 (eGFR, ml/min/1.73 m 2 ) and serum creatinine concentration on or within 2 days of admission. We also collected preadmission blood pressure, body mass index, hemoglobin level, and platelet count, if available, or within 2 days of admission.

We characterized pre-admission receipt of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, beta-blockers, calcium channel blockers, diuretics, aldosterone receptor antagonists, non-aspirin antiplatelet agents, statins, and other lipid-lowering agents based on data on estimated day supply per dispensed prescription and refill patterns in pharmacy databases using validated methods. 22 Baseline oral anticoagulant use was defined as a dispensed prescription covering any part of the 60 days before or on index date. Parenteral (heparin, fondaparinux, enoxaparin, dalteparin, and tinzaparin) or oral (warfarin, dabigatran, rivaroxaban, apixaban, edoxaban, and betrixaban) anticoagulant use during the index hospitalization was defined as dispensing during the hospital stay but before a VTE if one occurred. Anticoagulant exposure at discharge was characterized as dispensing on or within 7 days after discharge but before a VTE event, if one occurred during this period.

Analyses were performed using SAS 9.4 (Cary, N.C.). Baseline characteristics were presented as means with standard deviations (SD) or medians with interquartile ranges (IQR) for continuous variables, and frequencies with percentages for categorical data. Any missing data were assigned to a missing or unknown category. Given the large sample size, we compared characteristics between matched patients using Cohen's D value 23,24 for continuous variables and Cramér's V 25,26 for categorical variables, with a value >0.10 considered potentially significant. We used the Kruskal-Wallis test to compare median values, with a P<0.05 considered significant.

We calculated rates (per 100 person-years) with associated 95% confidence limits for VTE and death at 30 days, and we compared the cumulative incidence function of VTE by group using Gray's test. Given the concern for competing risk of death that may not be due to VTE associated with Covid-19, we performed multivariable Fine-Gray subdistribution hazard J o u r n a l P r e -p r o o f modeling 27 to account for competing risk of death and potential confounders, with covariates included that significantly differed between groups.

Finally, among the subgroup of Covid-19 patients, we conducted a Fine-Gray subdistribution hazard model to identify multivariable predictors of VTE using patient characteristics in Table 1 as candidate predictors.

Between February 1-August 31, 2020, we identified 7,050 eligible hospitalized adults with laboratory-confirmed Covid-19. We matched 6,319 (89.6%) Covid-19 patients to a hospitalized control without evidence of Covid-19 based on age, gender, race/ethnicity, level of acute illness severity, and calendar month of hospitalization (Figure 1 ). Of note, 91.4% of matched Covid-19 patients were considered severe (i.e., oxygen saturation <94% or receipt of high-flow oxygen or mechanical ventilation). 28 Matched patients were similar at baseline, although Covid-19 patients were less likely to have cancer and more likely to have sepsis diagnosed during the index hospitalization and to have a higher body mass index ( Table 1) . Among tested patients, those with Covid-19 had slightly lower median serum creatinine concentration, but higher hemoglobin and platelet count compared to matched controls.

During the index hospitalization, Covid-19 patients were more likely to receive parenteral anticoagulant therapy compared with those without evidence of Covid-19, but there was no difference in the receipt of anticoagulants at discharge ( Table 1) . Compared with matched controls, Covid-19 patients had longer median length of stay and were more likely to die during the index hospitalization or be discharged to a skilled nursing facility ( 32 Abnormalities in selected coagulation parameters (e.g., D-dimer, fibrin degradation product, fibrinogen, prothrombin time, activated partial thromboplastin time) also appear to be common, with significantly worse abnormalities in these parameters in fatal cases. 3 In addition, a high proportion of selected severe Covid-19 patients had potentially pathogenic acquired antiphospholipid antibodies. 33,34 Importantly, however, the patterns of derangement in coagulation and inflammatory pathways associated with severe Covid-19 may vary from models described for sepsis-induced coagulopathy or disseminated intravascular coagulation, 35,36 which could have important management implications given the need for robust randomized trial evidence for effective VTE prevention strategies across the spectrum of Covid-19 severity. 37,38

We studied a carefully matched, demographically diverse cohort with comprehensive longitudinal data through 30 days to facilitate evaluation of the risk of VTE associated with Covid-19 and its severity that extended beyond the index hospitalization. We used a combination of diagnosis codes and a validated natural language processing algorithm applied to EMR data to identify validated acute VTE. We addressed the competing risk of death to more accurately evaluate the excess risk of VTE with Covid-19. Finally, we identified independent predictors of VTE associated with Covid-19 that are readily available clinically.

Our study also had limitations. To maximize generalizability, we included hospitalized adults as controls if they met matching criteria and did not have a SARS-CoV-2 test performed, but this only affected 13% of all controls and if some of these patients had undiagnosed Covid-19, this would bias our results to the null. Given the high rate of anticoagulant use during the index hospitalization in the overall cohort and preferentially higher use in Covid-19 patients, the excess risk associated with Covid-19 may be underestimated. Similarly, our models accounted for the competing risk of death from any cause, and it is possible that there were some deaths due to undiagnosed VTE, but this tends to bias results towards the null given the substantially higher rate of death in Covid-19 patients. Given that we studied only hospitalized adults, we were unable to evaluate whether the risk of VTE associated with Covid-19 differs in less severe outpatients with Covid-19. While our study was performed within integrated healthcare delivery systems caring for populations that are highly representative of the California-wide population, our results may not completely generalize to all countries and health systems.

In a large, diverse matched cohort of hospitalized adults, Covid-19 was independently associated with a higher risk for VTE, and several patient characteristics were linked to higher J o u r n a l P r e -p r o o f 

Centers for Disease Control and Prevention. Excess deaths associated with COVID-19

COVID-19 and Excess All-Cause Mortality in the US

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19

Coagulation abnormalities and thrombosis in patients with COVID-19

Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis

Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients: An NATF Anticoagulation Action Initiative

Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data

Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology

The Cardiovascular Research Network: a new paradigm for cardiovascular quality and outcomes research

Creating a research data network for cardiovascular disease: the CVRN

Risk-adjusting hospital mortality using a comprehensive electronic record in an integrated health care delivery system

Validity of Using Inpatient and Outpatient Administrative Codes to Identify Acute Venous Thromboembolism: The CVRN VTE Study

American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism

Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study

Use of commercial record linkage software and vital statistics to identify patient deaths

The California Automated Mortality Linkage System (CAMLIS)

The authors would like to thank Rong Wei and Chengyi Zheng for their technical or administrative assistance. Dr. Alan S. Go